ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 12, Issue 548, Pages eabc4220
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-06-18
DOI
10.1126/scitranslmed.abc4220
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
- (2020) Jing Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review
- (2019) Jean-Michel Lavoie et al. JOURNAL OF UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- ARID1A loss in cancer: Towards a mechanistic understanding
- (2018) Radhika Mathur PHARMACOLOGY & THERAPEUTICS
- Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
- (2018) Dharmesh Gopalakrishnan et al. Therapeutics and Clinical Risk Management
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
- (2018) Li Wang et al. Nature Communications
- Maftools: efficient and comprehensive analysis of somatic variants in cancer
- (2018) Anand Mayakonda et al. GENOME RESEARCH
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers for immunotherapy in bladder cancer: a moving target
- (2017) David H. Aggen et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Therapy and the Search for Predictive Biomarkers
- (2016) Padmanee Sharma CANCER JOURNAL
- Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select
- (2016) Charles G. Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
- (2014) Edward C. Stack et al. METHODS
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More